Live Attenuated Vaccines for Respiratory Syncytial Virus

摘要: In the five decades since identification of respiratory syncytial virus (RSV) as an important pediatric pathogen, no effective vaccine has been developed. Previous attempts to develop inactivated RSV vaccines resulted in vaccine-enhanced disease, resulting a greater focus on generation live attenuated vaccines. However, identifying candidate that is appropriately and sufficiently immunogenic proven be difficult. Recently, reverse genetics systems have developed for RSV, allowing researchers introduce specific mutations into genomes recombinant candidates. These provide means determining effects known attenuating novel methods without decreasing immunogenicity. addition, different can combined single genome fine-tune level attenuation immunogenicity achieve proper balance viable candidate. Current research includes investigation point responsible temperature sensitivity, nontemperature-sensitive mutations, deletion nonessential viral genes play roles RNA synthesis and/or inhibition innate immune responses. Development will likely rely using optimize candidate, while preserving replication vitro.